The use of prostatilen in treating patients with prostatic diseases
Vozianov AF, Gorpinchenko II, Boĭko NI, Drannik GN, Khavinson VKh · 1991 · Urol Nefrol (Mosk) (6):43-46. PMID 1823683
What does this source report?
Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.
- Population and setting
- 37 patients with chronic prostatitis and 15 with prostatic adenoma
- Evidence type
- Uncontrolled human report
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Small mixed clinical groups; control methods and adverse-event ascertainment unclear from the abstract.
- The tissue extract is not the synthetic peptide Prostamax.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Vozianov AF, Gorpinchenko II, Boĭko NI, Drannik GN, Khavinson VKh. The use of prostatilen in treating patients with prostatic diseases Urol Nefrol (Mosk) (6):43-46. PMID 1823683 1991.
Molekul research summary: https://molekul.io/research/bio-1823683. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry